Veeva Introduces Vault Basics for Biotechs
Delivers industry-leading Vault applications in a turnkey solution with no implementation costs for simple adoptionPLEASANTON, Calif., May 16, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today an
Beacon Biosignals Selected by Longboard Pharmaceuticals to Advance Understanding of Epilepsy and Related Conditions
BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Beacon Biosignals announced a strategic partnership with Longboard Pharmaceuticals, Inc. that combines Longboard's drug development expertise with Beacon's neurophysiological
HC Wainwright & Co. : The Longboard Pharmaceuticals (LBPH.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $60.00.
HC Wainwright & Co. : The Longboard Pharmaceuticals (LBPH.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $60.00.
HC Wainwright & Co. Reiterates Buy on Longboard Pharmaceuticals, Maintains $60 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and maintains $60 price target.
Analysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Longboard Pharmaceuticals (LBPH) and Travere Therapeutics (TVTX)
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards
Buy Rating Affirmed for Longboard Pharmaceuticals Amidst Positive Clinical Progress and Market Potential for Bexicaserin
Longboard Pharmaceuticals Inc. (LBPH) Q1 2024 Earnings: Financial and Strategic Developments
Wedbush: The Longboard Pharmaceuticals (LBPH.US) rating was maintained, and the target price was adjusted from superior to superior market rating, and the target price was adjusted from $32.00 to $34.00.
Wedbush: The Longboard Pharmaceuticals (LBPH.US) rating was maintained, and the target price was adjusted from superior to superior market rating, and the target price was adjusted from $32.00 to $34.00.
Wedbush Maintains Outperform on Longboard Pharmaceuticals, Raises Price Target to $34
Wedbush analyst Laura Chico maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and raises the price target from $32 to $34.
Longboard Pharmaceuticals (LBPH) Receives a Buy From Wedbush
Longboard Pharmaceuticals (LBPH.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share of -$0.42, previous value of -$0.56, expected value of -0.52 dollars.
Longboard Pharmaceuticals (LBPH.US): The 2024 Q1 financial report achieved revenue of $0, previous value of $0; earnings per share of -$0.42, previous value of -$0.56, expected value of -0.52 dollars.
Longboard Pharmaceuticals Q1 EPS $(0.42) Beats $(0.52) Estimate
Longboard Pharmaceuticals (NASDAQ:LBPH) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.52) by 19.23 percent. This is a 25 percent increase over losses
Longboard Pharmaceuticals 1Q Loss/Shr 42c >LBPH
Longboard Pharmaceuticals 1Q Loss/Shr 42c >LBPH
Press Release: Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates -- Bexicaserin (LP352) Phase 1b/2a PACIFIC Study positive topline data in participants
Longboard Pharmaceuticals (LBPH.US) was first covered by Baird, which gave it an superior market rating, with a target price of $36.00.
Longboard Pharmaceuticals (LBPH.US) was first covered by Baird, which gave it an superior market rating, with a target price of $36.00.
Baird Initiates Coverage On Longboard Pharmaceuticals With Outperform Rating, Announces Price Target of $36
Baird analyst Joel Beatty initiates coverage on Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform rating and announces Price Target of $36.
Buy Rating Affirmed on Longboard Pharmaceuticals With Promising Bexicaserin Developments and Regulatory Milestones Ahead
Institutional Investors in Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) See US$68m Decrease in Market Cap Last Week, Although Long-term Gains Have Benefitted Them.
Key Insights Institutions' substantial holdings in Longboard Pharmaceuticals implies that they have significant influence over the company's share price 50% of the business is held by the top 8 shar
HC Wainwright & Co. Reiterates Buy on Longboard Pharmaceuticals, Maintains $60 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and maintains $60 price target.
No Data